September 9, 2019 1:45pm
Short expectations are mixed and mired in the mud of electronic trading
I’m apprehensive as the quarter (Q3) moves forward and to its close
It's a daunting task to understand risk, seeing the unforeseen; when you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
Dow futures are UP +0.26% (+69 points), S&P futures are UP +0.09% (+3 points) and NASDAQ futures are DOWN -0.17% (-14 points)
Markets are split with futures on the Dow and S&P up as the NASDAQ lags
European markets are acting cautiously as investors question the issues of Brexit happening and its after effects and surrounding politics
Asia pacific markets are higher
Watch and wait … if an opening appears take it but, I am still apprehensive about any upside in the cell and gene therapy sector!
From Friday’s evening post, “back to a softening sector as the NASDAQ dips.”
• The NASDAQ was down -13.75 or -0.17% to 8,103.07;
• The IBB closed down -0.15% while the XBI also closed down -0.87%
• The close was negative with an A/D Line of 16/26 and 1 flat and 2 acquired;
• The range of the 16 upside was +0.21% (ONCE) to +17.50% (AGTC) while the 26 downside ranged from -0.39% (MESO) to -6.74% (RENE.L);
• 4 out of the 16 upside had higher than the 3 month average volume;
• 9 out of the 26 downside had higher than the 3 month average volume;
Q3/19 to date:
- In July, there were 9 positive, 1 holiday and 13 negative closes;
- In August there had been 12 negative and 10 positive closes
- September started with 2 positive, 1 holiday and 2 negative close
Companies in my headlights – It’s your decision; I provide an idea and context:
*** Let the machines and algorithms do their worst – there is always a comeback from a depreciating dive ***
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.